Grant: Operating Grant - PA: Cancer Research (bridge funding)
Sunnybrook Research Institute (Toronto, Ontario)
$100,000.00
EAR-2 in normal haematopoiesis and leukaemogenesis
FY 2010-11
Summary
In the past two decades, many advances have been made in our understanding of acute myelogenous leukaemia (AML). However, these advances failed to translate into major improvements in the treatment of AML. We are working to identify characteristics of AML that can be targeted by new and more effective drugs. One potential target we have found is EAR-2. We have shown that EAR=2 is expressed highly in AML and that unregulated expression of EAR-2 in mouse bone marrow cells causes AML. In this proposal we describe experiments that will show how EAR-2 causes AML, and what role EAR-2 might play in normal blood formations. This work will set the stage for the development of drugs that target EAR-2.
Department
Program
Operating Grant - PA: Cancer Research (bridge funding)
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
220358
Name
Wells Richard A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Molecular & Cellular Biology of Cancer
Projecttitle
EAR-2 in normal haematopoiesis and leukaemogenesis
Programtype2
Operating Grants
Orgnameinp2
Sunnybrook Research Institute (Toronto, Ontario)
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Cancer Research (bridge funding)
Keyworddelim
Actue Myelogenous Leukaemia; Clonogenicity; Differentiation; Ear-2; Haematopoietic Stem Cell; Nuclear Receptor
Abstract
In the past two decades, many advances have been made in our understanding of acute myelogenous leukaemia (AML). However, these advances failed to translate into major improvements in the treatment of AML. We are working to identify characteristics of AML that can be targeted by new and more effective drugs. One potential target we have found is EAR-2. We have shown that EAR=2 is expressed highly in AML and that unregulated expression of EAR-2 in mouse bone marrow cells causes AML. In this proposal we describe experiments that will show how EAR-2 causes AML, and what role EAR-2 might play in normal blood formations. This work will set the stage for the development of drugs that target EAR-2.
Competitiondate
201009
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wells, Richard A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
